Association between low-dose acetylsalicylic acid reinitiation and the risk of myocardial infarction or coronary heart disease death

Abstract

Background

In secondary cardiovascular prevention, discontinuation of acetylsalicylic acid (ASA) is associated with an increased risk of cardiovascular events. This study assessed the impact of ASA reinitiation on the risk of myocardial infarction and coronary heart disease death.

Methods

Patients prescribed ASA for secondary cardiovascular prevention and who had had a period of ASA discontinuation of ≥90 days in 2000–2007 were identified from The Health Improvement Network (N = 10,453). Incidence of myocardial infarction/coronary heart disease death was calculated. Survival analyses using adjusted Cox proportional hazard models were performed to calculate hazard ratios and 95% confidence intervals for the risk of myocardial infarction/coronary heart disease death associated with ASA use patterns after the initial period of discontinuation. Individuals who were prescribed ASA during follow-up were considered reinitiators.

Results

The incidence of myocardial infarction/coronary heart disease death was 8.90 cases per 1000 person-years. Risk of myocardial infarction/coronary heart disease death was similar for current ASA users, who had been continuously exposed since reinitiation, and patients who had not reinitiated ASA (hazard ratio 1.27, 95% confidence interval 0.93–1.73). Among reinitiators, an additional period of ASA discontinuation was associated with increased risk of myocardial infarction/coronary heart disease death compared with no reinitiation (current users: hazard ratio 1.46, 95% confidence interval 1.13–1.90; noncurrent users: hazard ratio 1.70, 95% confidence interval 1.31–2.21).

Conclusions

ASA reinitiation was not associated with a decreased risk of myocardial infarction/coronary heart disease death. This may be explained by confounding by indication/comorbidity, whereby higher-risk patients are more likely to reinitiate therapy. An additional period of ASA discontinuation among reinitiators was associated with an increased risk of myocardial infarction/coronary heart disease death.

Keywords

Acetylsalicylic acid coronary heart disease death discontinuation myocardial infarction reinitiation

Get full access to this article

View all access options for this article.

References

Perk

De Backer

Gohlke

. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635–1701.

Smith

Jr Benjamin

Bonow

. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458–2473.

García Rodríguez

Cea Soriano

Martín-Merino

. Discontinuation of low dose aspirin and risk of myocardial infarction: Case–control study in UK primary care. BMJ 2011; 343: d4094.

García Rodríguez

Cea Soriano

Hill

. Increased risk of stroke after discontinuation of acetylsalicylic acid: A UK primary care study. Neurology 2011; 76: 740–746.

Biondi-Zoccai

Lotrionte

Agostoni

. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667–2674.

Maulaz

Bezerra

Michel

. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005; 62: 1217–1220.

Sibon

Orgogozo

. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 2004; 62: 1187–1189.

Martin-Merino

Johansson

Nagy

. Represcription of low-dose acetylsalicylic acid after discontinuation in patients receiving treatment for secondary cardiovascular disease prevention in the UK. Am J Cardiovasc Drugs 2014; 14: 319–326.

Bourke

Dattani

Robinson

. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004; 12: 171–177.

10.

Lewis

Schinnar

Bilker

. Validation studies of The Health Improvement Network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16: 393–401.

11.

Stuart-Buttle

Read

Sanderson

. A language of health in action: Read codes, classifications and groupings. Proc AMIA Annu Fall Symp 1996, pp. 75–79.

12.

Gemscript. In Practice Systems Ltd – Gemscript 2014. Available from: http://www.resip.co.uk/gemscript.

13.

Martín-Merino

Johansson

Bueno

. Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: Incidence and predictors in patients with cardiovascular disease. Prag Obs Res 2012; 3: 1–9.

14.

Charlson

Pompei

Ales

. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373–383.

15.

Townsend

Phillimore

Beattie

. Health and deprivation: Inequality and the North, London: Croom Helm, 1988.

16.

Fine

Gray

. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

17.

Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.

18.

Baigent

Blackwell

Collins

. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–1860.

19.

García Rodríguez

Tacconelli

Patrignani

. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 52: 1628–1636.

20.

García Rodríguez

Varas-Lorenzo

Maguire

. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109: 3000–3006.

21.

Bedson

Whitehurst

Lewis

. Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease. Br J Gen Pract 2001; 51: 1001–1003.

22.

Cea Soriano

Bueno

Lanas

. Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation. Thromb Haemost 2013; 110: 1298–1304.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.15 MB